

File No. 27(2)/ 2017-Div-III/NPPA
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

5th/3rd Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi-110001

Date: 20.02.2018

Office Memorandum

In recent months Delhi/N.C.R witnessed some unfortunate deaths because of dengue and other ailments in four reputed private hospitals. In each case, NPPA got complaints of overpricing and inflated bills from the relatives of deceased patients. NPPA, within its jurisdiction under Drug Prices Control Order, 2013 had asked for details of billing from these hospitals and analyzed the same in great detail. Data of one of the hospitals was put in public domain vide O.M. No 27(2)/ 2017-Div-III/NPPA Dated 15.12.2017. NPPA has received applications under RTI Act and some relatives of the patients have met Chairman, NPPA seeking action in the matter.

Subsequent to disclosure of data of one hospital which had not requested confidentiality, the other hospitals submitted data with a request that name of the hospital should not be put up in public domain. Since the analysis done by NPPA is a matter of public concern, it is being put up in public domain with the objective of removing information asymmetry between patients and the hospitals and for greater transparency in healthcare system in public interest. Honoring the confidentiality requested by the other three hospitals, name of the hospitals is not being disclosed.

2. The information submitted by the hospital has been analyzed and tabulated into following categories provided as Tables:

A. Scheduled Formulations based on National List of Essential Medicines, 2015 (Schedule I of DPCO, 2013) and under price control.

B. Non-scheduled Formulations (Not under price control and out of Schedule 1 of DPCO, 2013)

C. Consumables not listed as drugs (neither under price control and nor under Schedule 1 of DPCO, 2013)

D. Medical devices (neither under price control and nor under Schedule 1 of DPCO, 2013)

3. The summarized table showing the breakup of the total amount billed to the patients in terms of various components of the hospital charges has been found to be as follows:

Sl.	Particulars	Amount	%
	a	b	c
1	Scheduled formulations	2,84,295.71	4.10%
2	Non-scheduled formulations	17,79,898.66	25.67%
3	Non-scheduled devices#	1,05,525.00	1.52%
4	Consumables*	6,63,175.06	9.56%
5	Diagnostics services	10,78,792.00	15.56%
6	Cost of procedures	7,91,912.00	11.42%
7	Consultation & Medical Supervision	8,82,432.00	12.72%
8	Equipment charges	5,16,771.00	7.45%
9	Room rent	8,04,850.00	11.61%
10	Surgery	27,113.00	0.39%
11	Total	69,34,764.43	100.00%

Non-scheduled devices include disposable syringes with or without needles, Catheter, I.V. Cannula, etc.

*Consumables include: surgical masks, hand gloves, etc.

(a) The total cost on scheduled medicines used in the treatment is only 4.10 % as compared to 25.67% on non-scheduled formulations. It is amply clear that for claiming higher margins, doctors-hospitals preferred prescribing and dispensing non-scheduled branded medicines instead of scheduled medicines while scheduled medicines under NLEM are supposed to cover all essential medicines.

This also indicates that the drug variants of scheduled (essential under NLEM) launched by manufacturers in the name of 'new drugs' and 'fixed dose combinations' in order to come out of price control have become the preferred choice for manufacturing and medical fraternity thereby diluting the purpose of putting these drugs under essential category under NLEM where specification of dosage and forms(as essential) makes it easier for manufacturers to launch a different dose or form and come out of price control with an added benefit of permissible 10% annual increase in MRPs.

Under NLEM, 2015, NPPA has capped the prices of 871 essential drugs along with approval of retail prices of 642 drugs as 'new drugs' during the same period because of statutory provisions. This trend of migration from scheduled to non-scheduled category is reflected in the growth rate of NLEM and non NLEM drugs in the year 2017 where the rate of growth of non NLEM drugs is almost double the rate of NLEM drugs. This issue needs to be addressed through policy intervention.

(b) Institutional bulk purchase by private hospitals, which in most cases keep a pharmacy of its own, makes it easier for them to get very high profit margins and indulge into profiteering on drugs and devices even without need to violate the MRPs which is already enough inflated. Industry, in order to get bulk supply orders is in a way 'forced' to print higher MRPs as per the 'market requirements'. This is a clear case of market distortion where manufacturers after accounting for their profits print inflated MRPs to meet out the demands of a distorted trade channel without getting any benefits from this 'artificial inflation' and patients have to incur huge out of pocket expenditure in hospitalization cases and also otherwise where they are not allowed to buy drugs from outside or go by the physician's branded prescription.

It is to be noted that trade margins after selling it to stockists does not become part of the balance sheet of the manufacturers or importers and this is how present pricing system based on averaging of price to retailers (PTRs) rarely hurts the industry margins. The PTR based averaging method leaves even price control drugs with huge trade margins in about 20% cases as can be seen in the Table 'A'.

(c) In most of the cases of scheduled and nonscheduled drugs under formal monitoring of NPPA, the hospital purchase prices are invariably often lower than the 'prices to stockists' (PTS) offered by the manufactures in retail chain except for a few exceptions. This explains the variation in prices of drugs in open market and the retail shops and the hospitals and the truth behind various 'concessions'

offered by retailers and in some cases even private hospitals on the overall bill as part of its 'charity'.

(d) Apart from non-scheduled drugs, the charges on consumables is one tenth of the total bills and more than two times of the expenditure on scheduled (essential) drugs. These consumables are not under any kind of price control or monitoring of MRPs since these are not even listed as 'drugs' under Drugs & Cosmetics Act. NPPA can neither monitor the MRPs nor bring these disposables under price control even in public interest under extraordinary conditions.

(e) Diagnostics services constitute more than 15% of the total cost. In random checks by NPPA, the charges were invariably found to be higher than diagnostics facilities provided by other independently run private centers. Diagnostics services along with all other charges by hospitals are beyond the purview of NPPA and the Central Government and can be regulated only through State specific laws whether through adoption of central model 'Clinical Establishment Act, 2010 and corresponding Rules' or otherwise through its own specific legislation by State Governments which is already in existence in every State requiring enabling statutory provisions

(f) The profit margins in the non-scheduled devices used in the three cases (syringes, cannula and catheters) are exorbitant and clearly a case of unethical profiteering in a failed market system. On being brought to notice by NPPA, some manufacturers are said to have brought down prices on their own while a small group of manufacturers are said to be resisting the self-regulation and have requested NPPA for its intervention in rationalizing the trade margins so that it is compulsorily complied by all. NPPA is closely monitoring the developments.

(g) The total expenditure on drugs and devices and diagnostics is substantially high (46%) and does not make part of the publicized 'estimate' or 'package' (in case of implants) by the hospitals in comparison to "procedures" (11.42%), room rent (11.61%) etc. which are the more visible components. In all these cases, the patients have complained that the initial estimate of expenditure got inflated by 3-4 times. In one case the hospital had not billed the relatives of the deceased under extraordinary circumstances.

(h) Most of the drugs, devices and disposables were used and sold by the hospitals from their own in-house pharmacies and the patients were given no choice or

opportunity to procure these articles from outside the hospitals where prices are supposed to be lower in most cases because of some 'discounts'.

(i) Last but not the least, the major beneficiaries of profits in all these cases because of inflated MRPs have been hospitals rather than drugs and devices' manufacturers. The violation of ceiling price and corresponding MRPs is detected only in very few cases which shall be pursued further by NPPA for recovering the overcharging amounts from defaulters.

Anand 20/02/18
(Anand Prakash)
Deputy Director

Table A

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for
Scheduled Formulation

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS) as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
1	Propofol Inj 10mg/ml-20ml Vial	20 ML	2	Claris Injectables Ltd	80.96	40.95	187.28	374.56	357%	131%
2	Verfen 50MCG/ML 10ML INJ(Fentanyl) INJ	50 MCG/ML	8	VERVE	NA	49.84	225	1800.00	351%	NA
3	Nanzidone Solution 10% (Povidone-Iodine Solution)	1	150	Nanz Med	NA	0.23	1.03	154.35	348%	NA
4	Amlip 5mg Tab (Amlodepin)	5 MG	16	Cipla Ltd.	0.47	0.56	2.5	40.00	346%	438%
5	TRANEMIC,500MG/5ML	500MG/5ML	31	SAMARTH PHARMA PVT. LTD.	23.20	15.75	69.77	2162.87	343%	201%
6	Tazira Lyo	4.5GM	2	Abbott	144.00	100.92	446.21	Not billed	342%	210%
7	Normal Saline 0.45% 500ml IV Glass Bottle	500 ML	5	DENISCHEM LAB LTD	16.74	31.36	130.5	652.50	316%	680%
8	Atacurium 50mg(Atracurium Besylate)Inj1s	50 mg	6	Themis	75	61.6	254.9	1529.40	314%	240%
9	FENSTUD,500MCG	500MCG	21	RUSAN PHARMACEUTICALS	NA	56.00	220	4625.00	293%	NA
10	Verfen (Fentanyl)10ml Inj.	10ml	2	Verma Pharmaceuticals	NA	56.44	220	440.00	290%	NA

Table A

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for

Scheduled Formulation

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS) as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
11	Adrenor 4mg/2ml(Noradrenaline)Inj	4mg/2ml	12	SAMARTH LIFESCIENCES	7.79	13.44	52.35	628.20	290%	572%
12	Vanking 500mg Inj	500 GM	16	Neon Labs	72.90	69.30	267.45	4279.20	286%	267%
13	Verfen (Fentanyl)10ml Inj.	10ml	66	Verma Pharmaceuticals	NA	60.20	225	14850.00	274%	NA
14	Pantodac Inj 40mg(Pantoprazole) Inj	40 mg	20	ZYDUS	19.26	12.9	45.25	905.00	251%	135%
15	Verfen 50MCG/ML 2ML(Fentanyl) INJ	50MCG/ML 2ML	2	VERVE	NA	12.99	45.1	90.20	247%	NA
16	ATACURIUM,50MG	50MG	5	THEMIS MEDICARE LTD	75.00	77.28	254.9	1274.50	230%	240%
17	Propofol Inj 10mg/ml-20ml Vial	20 ML	1	Claris Injectables	80.96	43.68	143	143.00	227%	77%
18	ADRENOR 2ML INJ (NOR- ADRENALINE)	3 ML	29	Samarth Pharma Pvt Ltd.	13.64	15.68	51.19	1484.51	226%	275%
19	TAZACT,4.5GM	4.5GM	9	CIPLA LTD.	153.44	134.40	427.97	3851.73	218%	179%
20	THEMIPEN,40MG	40MG	9	THEMIS MEDICARE LTD	NA	13.22	41.9	377.10	217%	NA
21	PANSALVE,40MG	40MG	13	EMCURE PHARMACEUTICALS	11.04	13.72	43.35	563.55	216%	293%

Table A

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for

Scheduled Formulation

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS)as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
22	Artacil 25mg(Artacurium Besyl)Inj	25 mg	1	NEON LABORATORIES LTD	61.74	41.44	128.8	128.80	211%	109%
23	Verfen (Fentanyl) 10ml Inj	10 ML	1	Verve Pharmaceuticals	NA	71.40	220	220.00	208%	NA
24	Mucinac 5ml (N-Acetylcysteine) Inj	5ml	4	CIPLA LTD	70.17	35.73	109.15	436.60	205%	56%
25	Artacil 50mg(Atracurim Besyl)Inj	50mg	82	NEON LABORATORIES LTD	113.22	84	256.6	21041.20	205%	127%
26	Mezoram Inj 10ml Vial	10 ML	1	Neon Labs	28.35	21.00	63	63.00	200%	122%
27	CALCIUM GLUCONATE	10ML	26	RATHI	NA	3.69	11	286.00	198%	NA
28	Dextrose 25 % 25 ML(Dext I.V)(Rathi)Inj	25 ml	1	Rathi	NA	8.19	24	24.00	193%	NA
29	DOMIN,200MG,DOPAMINE,5 ML,INJECTION,NEON	200MG	33	NEON	10.08	9.01	26.35	869.55	192%	161%
30	Fresofol Mct/Lct 20 ML(Profol)Inj	20ml	2	FRESENIUS KABI	90	99.29	286	572.00	188%	218%
31	Ringer Lactate 500ml IV Plastic Bottle	500 ML	3	Otsuka Pharmaceuticals	NA	21.11	58.12	174.36	175%	NA
32	NORAD,2MG/ML	2MG/ML	45	NEON	19.80	18.76	51.2	2304.00	173%	159%

Table A

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for

Scheduled Formulation

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS)as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
33	NEOVEC,4MG	4MG	60	NEON	37.80	31.21	85	5100.00	172%	125%
34	Emeset 4 ml Inj	4 ML	1	Cipla Ltd.	14.95	9.05	22.81	22.81	152%	53%
35	Trofentyl (Fentanyl) 2ml Inj	2 ML	2	Troikaa	14.00	18.90	45.86	90.92	143%	228%
36	Esmeron 50mg/5ml Inj	5 ML	1	Infar	239.99	157.50	382.00	382.00	143%	59%
37	Potcl 10ml Injection	10 ML	8	Neon Labs	13.32	10.50	23.56	188.48	124%	77%
38	Atorlip 40mg tab	40 MG	2	Cipla Ltd.	12.61	8.50	18.80	17.00	121%	49%
39	RINHEPA,5000IU,HEPARIN,1X1,INJECTION	5000IU	3	UNITED BIOTECH PVT. LTD.	49.06	35.28	77.70	233.10	120%	58%
40	Neovac 10mg Inj	10 MG	11	Neon Labs	NA	80.85	176.00	1098.60	118%	NA
41	NEOVEC,10MG,VECURIUM BROMIDE,1X1,INJECTION	10MG	10	Neon Labs	81.00	81.62	176.00	1760.00	116%	117%

Table B

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for **Non-Scheduled Formulation**

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS) as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
1	Adrenor 2ml Inj (Nor-Adrenaline)	2 ML	28	Samarth Pharma Pvt Ltd.	13.64	14.70	189.95	5,318.60	1192%	1293%
2	Todaycef 1gm Injection	1 GM	2	Akumentis Healthcare Pvt Ltd	NA	40.32	430	860.00	966%	NA
3	DOTAMIN	200MG	2	NEON	NA	28.35	287.50	575.00	914%	NA
4	Voritrop 200mg Tablet	200mg	13	Intas	NA	123.20	1,240.00	16,120.00	906%	NA
5	EMTIG 50MG INJECTION	50 MG	10	Emcure Pharmaceuticals Limited	346.82	442.40	4,247.60	42,476.00	860%	1125%
6	TODAYCEF 1GM INJECTION	2 GM	15	Akumentis Healthcare Pvt Ltd	NA	78.40	690	10,350.00	780%	NA
7	Meroza XP 1.5gm Injection	1.5 GM	9	Cadila Pharmaceuticals Ltd.	2145.45	414.40	3562.5	32,062.50	760%	66%
8	TAMIN (PB),1GM,	1GM	3	CLARIS INJECTABLES LIMITED	120.75	36.29	310.00	930.00	754%	157%
9	1gm(Meropenem)Inj1s	1gm	0	ZYDUS CADILA	360	391.84	3242	0.00	727%	801%
10	Treonam 1gm(Meropenem)Inj	1gm	4	Aurbindo Pharma	323.48	403.20	3333	13332.00	727%	930%
11	MEROCRIT,1GM	1GM	24	CIPLA LTD.	520.1	404.32	3,112.50	74,700.00	670%	498%
12	Omnikacin 500 mg Inj	500 MG	2	CIPLA	75.43	15.75	110	Not billed	598%	NA
13	Merocrit 500mg (Meropenem) Inj	500mg	6	CIPLA LTD	370.08	246.96	1716.5	10299.00	595%	364%
14	Merocrit 1gm (Meropenem) Inj	1gm	8	CIPLA LTD	520.1	450.02	3112.5	24900.00	592%	NA

Table B

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for **Non-Scheduled Formulation**

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS) as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
15	Linoplus Injection	300 ML	2	Abbott Healthcare Pvt. Ltd.	287.43	68.25	472	944.00	592%	64%
16	Pantate Tab	40 MG(1X10)	4	DR.MORPEN	NA	1.17	7.9	Not billed	575%	NA
17	Criticef 1.5 gms Inj	1.5 GM	2	AKUMENTIS	244.53	61.60	395	Not billed	541%	38.96
18	PROCTOCLYSIS,	0	1	U.S.PHARMA	NA	7.84	50.00	50.00	538%	NA
19	Treonam 500Mg(Meropenem)Inj	500mg	1	Aurbindo Pharma	197.33	296.80	1800	1800.00	506%	812%
20	Linoplus Injection	300 ML	8	Abbott Healthcare Pvt. Ltd.	287.43	73.50	435	3,480.00	492%	NA
21	Guficol Plus 1 MIU Injection	1 MIU	4	Gufic Pharma Ltd.	250	203.28	1145	4,580.00	463%	358%
22	Tigimax 50mg(Tigecycline) Inj	50mg	1	ABBOTT PIRAMAL	NA	617.40	3434	3434.00	456%	NA
23	Guficol Plus 1 MIU(Colistimetha Sodi)In	1MIU	20	GUFIC	552	207.20	1145	22900.00	453%	107%
24	LINOPLUS Infusion 600mg(Linezolid)Inj	600mg	11	ABBOTT	287.43	87.81	472	5192.00	438%	64%
25	Denilyte-P-Multilyte500ml-AquaPulsInj-PP	500 ml	3	DENIS CHEM	NA	30.80	164.2	492.60	433%	NA
26	Tazira LYO Injection	4.5 GM	12	Abbott Healthcare Pvt. Ltd.	144	81.90	427.96	5,135.52	423%	197%
27	Tazira LYO Injection	4.5 GM	25	Abbott Healthcare Pvt. Ltd.	144	81.90	427.96	10,699.00	423%	NA

Table B

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for **Non-Scheduled Formulation**

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS) as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
28	LEVOX	500mg/100ml	9	CLARIS OTSUKA PVT. LTD.	21.36	23.81	115.00	1,035.00	383%	NA
29	Vorier 200mg Injection	200mg	2	Zydus	NA	532.00	2500	5,000.00	370%	NA
30	COLYMONAS,1MIU	1MIU	20	GLENMARK PHARMACEUTICALS LTD.	270	212.80	997.50	19,950.00	369%	269%
31	T-Planin 200mg Inj	400 MG	16	Glenmark Pharmaceuticals Ltd.	405	367.50	1678.5	26,856.00	357%	314%
32	Tranemic 500 Mg 5ml(tranexamic Acid)Inj	500mg	41	SAMARTH LIFESCIENCES	23.2	15.75	71.13	2916.33	352%	NA
33	TPLANIN,400MG,	400MG	13	GLENMARK PHARMACEUTICALS LTD.	405	420.00	1,678.50	21,820.50	300%	NA
34	TAZIRA LYO,4.5GM	4.5GM	3	ABBOTT HEALTHCARE	144	112.00	436.39	1,309.17	290%	NA
35	PT2.25gm Inj	2.25 GM	10	GLAND	na	60.48	212.8	Not billed	252%	NA
36	MEDZOL,1MG/ML	1MG/ML	44	THEMIS MEDICARE LTD	20	17.92	58.67	2,581.48	227%	193%
37	SODIUM BICARBONATE	25 ML	2	RATHI	NA	7.38	24.00	48.00	225%	NA
38	Hepaglan 5000 i.u./5ml Injection	5 ML	2	Gland Pharmaceuticals	NA	30.45	98	196.00	222%	NA
39	Artacil 2.5ml Inj	2.5 ML	7	Neon Labs	61.74	42.00	126.4	884.80	201%	105%
40	VITAMIN K,,MENADIONE,1ML,INJECTION	1ML	18	RATHI	NA	2.02	6.00	108.00	197%	NA
41	NS,0.03,SODIUM CHLORIDE,100ML,IV FLUIDS	100ML	9	SKKL	NA	28.00	83.00	747.00	196%	NA
42	Esoz 40mg Inj	40 MG	10	Glenmark Pharmaceuticals Ltd.	45	37.80	98.38	983.80	160%	119%

Table B

Statement Showing Procurement Price of Hospital, Price to Stockists as per market based data and MRP / Billing Rate by Hospital for **Non-Scheduled Formulation**

SL	Name of medicines/Injections	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	Price to Stockists (PTS) as per the market based data (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Stockists (%)
a	b	c	d	e	f	g	h	i	j	k
43	Dalcinex 4ml Inj	4 ML	49	Cipla Ltd.	65.22	72.33	187.5	9,187.50	159%	NA
44	Hepaglan 25000 i.u./5ml Injection	5 ML	5	Gland Pharmaceuticals	NA	88.20	227.5	1,137.50	158%	NA

Table C

Statement Showing Procurement Price of Hospital and MRP / Billing Rate by Hospital for **Consumables (include: surgical masks, hand gloves etc.)**

SL	Name of consumables used/administered	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketin g company	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/ devices/u nit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurem ent price (%)
a	b	c	d	e	f	g	h	i
1	THREE WAY STOP COCK,BI VALVE,,GS-3040	GS-3040	39	ROMSONS	5.77	106.00	4,134.00	1737%
2	3 WAY STOP COCK WITH LEUR LOCK-ROMSONS		5	ROMSONS	5.82	106	530.00	1721%
3	3 WAY STOP COCK WITH EXTN. 10CM-ROMSONS		1	ROMSONS	16.56	225	225.00	1259%
4	PRESSURE MONITORING LINE,PM O LINE,200CM,GS 3036	200CM	70	ROMSONS	17.30	225.00	15,750.00	1201%
5	JUGLAR SET DISPOSABLE STERILE-I117-APEX		1	APEX	7.35	95	95.00	1193%
6	THREE WAY EXTENSION LINE,VEIN O LINE,10CM,GS 3034,	10CM	4	ROMSONS	18.48	225.00	900.00	1118%
7	THREE WAY EXTENSION LINE,VEIN O LINE,200 CM,GS 3034	200 CM	22	ROMSONS	23.10	250.00	5,500.00	982%
8	BED BATH WET WIPES 24CMX30CM-10S-BARODA		14	BARODA	33.04	350	4900.00	959%
9	BED BATH TOWELS/WIPES,ECO PROTECT,LARGE PACK OF 10	LARGE PACK OF 10	2	CARE NOW	33.60	350.00	700.00	942%
10	BLOOD TRANSFUSION SET LEUR LOCK-ROMSONS		6	ROMSONS	12.42	126	756.00	914%
11	TROLLEY COVER BLUE 100X200CM-I-116-APEX		1	APEX	16.05	150	150.00	835%
12	Wet Absorption Sheet/Drymax sheet(under Pad)- 60x90 cm- Tidy/DryPad	60X90 cm	110	Tidy	11.00	100.00	11,000.00	809%
13	UNDERPAD DISPOSABLE 60CMX90CM-ROMSONS		40	ROMSONS	12.27	108	4320.00	780%
14	Oxygen Face Mask Adult with Extra Long Tubing (300cm)	1	1	Lamed	26.41	230.00	230.00	771%
15	THREE WAY EXTENSION LINE,I-PEX,200CM,BEX-80	200CM	1	B L Lifescience	25.76	220.00	220.00	754%

Table C

Statement Showing Procurement Price of Hospital and MRP / Billing Rate by Hospital for **Consumables (include: surgical masks, hand gloves etc.)**

SL	Name of consumables used/administered	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketin g company	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/ devices/u nit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurem ent price (%)
a	b	c	d	e	f	g	h	i
16	LIQUID GEL ECG ELECTRODE MS005-NIKO		18	NIKO	2.97	25	450.00	742%
17	E.C.G. Electrodes Adult Lead Lok	1	37	Medico El Ltd	2.63	22.00	814.00	737%
18	UNDERPAD,MATTY,PACK of 10	UNDERPAD	2	ROMSONS	131.13	1,080.00	2,160.00	724%
19	Suction Catheter Thumb Control with Cap(TC) 12-Top	12fr	47	Polymed	7.13	58.00	2,726.00	713%
20	Suction Catheter Thumb Control with Cap(TC) 14-Top	14fr	70	Polymed	7.13	58.00	4,060.00	713%
21	THREE WAY STOP COCK - Top	1	2	Polymed	11.93	95.00	190.00	696%
22	Intrafix Safe Set-Intraflow AS:DEHP Free	1	47	ROMSONS	30.97	244.00	11,468.00	688%
23	OXYGEN FACE MASK,FLEXI MASK	PEDIATRIC	1	ROMSONS	24.68	190.00	190.00	670%
24	PRESSURE MONITORING LINE,I-PEX,200CM,BPT-80M	200CM	5	BL life Science	22.96	176.00	880.00	667%
25	GLOVES SURGICAL,TRUSKIN,SIZE 7	SIZE 7	6	Suture India	9.86	75.00	450.00	661%
26	GLOVES SURGICAL,TRUSKIN,SIZE 7,,STERILE LATEX POWDERED	SIZE 7	6	Suture India	9.86	75.00	450.00	661%
27	THREE WAY STOP COCK	1	12	B.Braun	14.70	110.00	1,320.00	648%
28	PRESSURE MONITORING LINE 200CM. M/F-BL-P		2	B.L	23.52	176	352.00	648%
29	PRESSURE MONITORING LINE 150 BLUE M/F-BL		1	B.L	23.52	176	176.00	648%
30	PM Line M to F 200cm	1	9	BL life Science	24.15	176.00	1,584.00	629%
31	Elastic Adesive Bandage 10CM	10CM	104	3M	0.87	6.31	656.24	625%

Table C

Statement Showing Procurement Price of Hospital and MRP / Billing Rate by Hospital for **Consumables (include: surgical masks, hand gloves etc.)**

SL	Name of consumables used/administered	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/marketing company	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)
a	b	c	d	e	f	g	h	i
32	Disposable Ventilator Tubing Circuit with HME Filter Adult- Portex/Flexicare	1	1	Intersurgical	194.25	1,400.00	1,400.00	621%
33	GLOVES EXAMINATION UNSTERILE,DR'S KONTROL,MEDIUM,PACK OF ONE,LATEX	MEDIUM	300	GANESH HEALTHCARE	1.34	9.50	2,850.00	609%
34	THREE WAY STOP COCK	1	59	B.Braun	15.68	110.00	6,490.00	602%
35	IV DRESSING FULLY TRANSPARENT,LEUKOMED,6CMX8CM,72390N00,DRESSING	6CMX8CM	2	BSN MEDICAL	14.59	100.00	200.00	585%
36	PM Line M to F 200cm	200cm	7	B L Lifescience	25.76	176.00	1,232.00	583%
37	Gloves-Sterile Latex Surgical:Prime Care:7.5:18gm	18gm	10	Suture India	8.92	60.00	600.00	573%
38	GLOVES EXAMINATION UNSTERILE,DR'S KONTROL,SMALL,PACK OF ONE,LATEX	SMALL	1200	GANESH HEALTHCARE	1.49	9.50	11,400.00	538%
39	PEDIA DRIP SET,,100ML+10 ML,SS-3058	100ML+10 ML	11	ROMSONS	31.47	181.00	1,991.00	475%
40	ALCOHOLIC SWAB	ALCOHOLIC SWAB	4	MAK MEDICAL	0.45	2.00	8.00	344%

Table D

Statement Showing Procurement Price of Hospital, Price to Distributors as per market based data and MRP / Billing Rate by Hospital for **non-scheduled Medical Devices (include disposable syringes with or without needles, Catheter, I.V. Cannula, etc.)**

SL	Name of devices used	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/market ing company	Price to Distributer as per data submitted by Company (PTD) (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/ devices/u nit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurem ent price (%)	Margin on Price to Distributor (%)
a	b	c	d	e	f	g	h	i	j	k
1	I.V INFUSION SET NON-VENTED,RMS INFUSION SET,,SS-3062	SS-3062	18	ROMSONS	5.20	8.39	115.00	2,070.00	1271%	2112%
2	IV SET VENTED RMS-ROMSONS-PBMS		18	ROMSONS	9.5	8.46	115	2070.00	1259%	1111%
3	SYRINGE DISPOSABLE WITH OUT NEEDLE	50ML	67	LIFELONG MEDITECH LTD	13.6	15.29	200.00	13,400.00	1208%	1371%
4	SYRINGE DISPOSABLE,LIFELONG-RP,50 ML WITH NEEDLE,1246,LUER MOUNT	50 ML WITH NEEDLE	60	LIFELONG MEDITECH LTD	13.6	15.29	200.00	12,000.00	1208%	1371%
5	SYRINGE DISPOSABLE,LIFELONG-RP,50 ML W/O NEEDLE,1286,LUER LOCK	50 ML W/O NEEDLE	20	LIFELONG MEDITECH LTD	13.6	15.90	205.00	4,100.00	1189%	1407%
6	SYRINGE DISPOSABLE LUER LOCK,,LIFELONG MEDITECH LTD.,,2ML	2ML	60	LIFELONG MEDITECH LTD	1.12	1.61	19.00	1,140.00	1080%	1596%
7	SYRINGE DISPOSABLE,LIFELONG-BLISTER PACK,1828,2 ML WITH MOUNTED NEEDLE,LUER LOCK	2 ML WITH MOUNTED NEEDLE	35	LIFELONG MEDITECH LTD	1.20	1.61	19.00	665.00	1080%	1483%
8	SYRINGE DISPOSABLE,LIFELONG-BLISTER PACK,1834,10 ML WITH MOUNTED NEEDLE,LUER LOCK	10 ML WITH MOUNTED NEEDLE	1	LIFELONG MEDITECH LTD	2.57	3.26	37.00	37.00	1035%	1340%
9	SYRINGE DISPOSABLE WITH NEEDLE,,LIFELONG MEDITECH LTD.,5ML,	5 ML WITH NEEDLE	21	LIFELONG MEDITECH LTD	1.66	2.07	23.00	483.00	1011%	1286%

Table D

Statement Showing Procurement Price of Hospital, Price to Distributors as per market based data and MRP / Billing Rate by Hospital for **non-scheduled Medical Devices (include disposable syringes with or without needles, Catheter, I.V. Cannula, etc.)**

SL	Name of devices used	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/market ing company	Price to Distributer as per data submitted by Company (PTD) (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/ devices/u nit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Distributor (%)
10	SYRINGE DISPOSABLE,LIFELONG-BLISTER PACK,1831,5 ML WITH MOUNTED NEEDLE,LUER SLIP	5 ML WITH MOUNTED NEEDLE	68	LIFELONG MEDITECH LTD	1.28	2.07	23.00	1,564.00	1011%	1697%
11	SYRINGE DISPOSABLE,LIFELONG-BLISTER PACK,1832,5 ML WITH MOUNTED NEEDLE,LUER LOCK	5 ML WITH MOUNTED NEEDLE	67	LIFELONG MEDITECH LTD	1.51	2.08	23.00	1,545.00	1006%	1423%
12	SYRINGE DISPOSABLE WITH NEEDLE,,,,,10ML,	10 ML WITH NEEDLE	1	LIFELONG MEDITECH LTD	2.21	3.21	35.00	35.00	990%	1484%
13	SUCTION CATH TC 12F-ROMSONS-PBMS	TC 12 F	1	ROMSONS	9.5	6.63	64	64.00	865%	574%
14	SUCTION CATH PLAIN 12 F-ROMSONS-PBMS	PLAIN 12F	13	ROMSONS	6.4	5.79	52	676.00	798%	713%
15	SUCTION CATH PLAIN 10 F-ROMSONS-PBMS	PLAIN 10F	24	ROMSONS	6.4	5.79	52	1248.00	798%	713%
16	SUCTION CATHETER TC 10F-ROMSONS	TC 12 F	1	ROMSONS	9.5	6.63	59	59.00	790%	521%
17	PHOTO FUSION IV SET-14230-POLYMED	SET 14230	5	POLYMED	20.43	25.76	215	1075.00	735%	952%
18	SYRINGE DISP W/O NEEDLE 10ML-303081-BD	10ml with Needle	143	BD	3.9	2.6	18.5	2645.50	612%	374%
19	SYRINGE UNOLOCK L/M W/O NEED2ML-DISPOVAN	2ml with Needle	139	HMD	1.54	1.24	8.5	1181.50	585%	452%
20	Syring L.Slip 5ml w. needle:Emerald (303079)-BD	5ml with needle	82	Becton Dickson	2.52	2.42	15.50	1,271.00	540%	515%
21	Syringe L.Slip 10ml w.needle, Emerald(303083)-BD	10ml with Needle	35	Becton Dickson	3.90	3.28	21.00	735.00	540%	438%
22	Syringe L.Slip 10ml w.needle	10ml with Needle	185	Hindustan Manufacturing Devices	3.71	3.21	20.00	3,700.00	523%	NA
23	Syringe L.Slip 5ml w. needle (Emerald) - BD	1	15	Becton Dickson	2.05	2.42	14.50	217.50	499%	607%
24	Syring L.Slip 5ml w. needle:Emerald (303079)-BD	5ml with needle	95	Becton Dickson	2.52	2.42	14.50	1,377.50	499%	475%

Table D

Statement Showing Procurement Price of Hospital, Price to Distributors as per market based data and MRP / Billing Rate by Hospital for **non-scheduled Medical Devices (include disposable syringes with or without needles, Catheter, I.V. Cannula, etc.)**

SL	Name of devices used	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/market ing company	Price to Distributer as per data submitted by Company (PTD) (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/ devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Distributor (%)
25	Syringe L.Slip 10ml w. needle (Emerald) - BD	1	32	Becton Dickson	3.90	3.27	19.50	624.00	496%	NA
26	Syringe L.Slip 10ml w. needle	1	100	Hindustan Manufacturing Devices	3.71	3.21	19.00	1,900.00	492%	412%
27	Syring L.Slip 2ml w. needle	2ml with needle	187	Hindustan Manufacturing Devices	1.96	1.59	9.00	1,683.00	466%	359%
28	SYRINGE UNOLOCK L/M W/O NEED5ML-DISPOVAN	5ml with Needle	146	HMD	1.96	1.7	9.5	1387.00	459%	NA
29	Syringe L.Lock2ml/3ml w.needle	3ml	2	Hindustan Manufacturing Devices	1.96	1.62	9.00	18.00	456%	359%
30	IV CANNULA ADULT VENFLON 22G-BD-PBMS	22G-BD	4	BD	39.05	23.84	132	528.00	454%	238%
31	Syringe L.Slip 2ml w. needle	1	118	Hindustan Manufacturing Devices	1.96	1.59	8.50	1,003.00	435%	334%
32	Mount Catheter Extendible	1	8	Lifeline	NA	52.56	280.00	2,240.00	433%	NA
33	I.V. Cannula (Vasofix Safety Flex) 20G - (B.Braun) \$	1	2	B.Braun	76	50.10	265.00	530.00	429%	249%
34	I.V. Cannula (Vasofix Safety Flex) 22G - (B.Braun)	1	1	B.Braun	76	50.10	265.00	265.00	429%	249%
35	T- Piece with in line Nebuliser kiT (2505/2605) + Inter Surgical	1	1	Inter Surgical	NA	68.25	350.00	350.00	413%	NA
36	IV Cannula 20G	1	2	Becton Dickson	39.05	24.22	120.00	240.00	395%	207%
37	Mount Catheter Extendible	1	15	Romson	49	59.84	289.00	4,335.00	383%	490%
38	Trach Vent + HME (41111) -	1	7	Hudson	NA	61.40	296.00	2,072.00	382%	NA

Table D

Statement Showing Procurement Price of Hospital, Price to Distributors as per market based data and MRP / Billing Rate by Hospital for **non-scheduled Medical Devices (include disposable syringes with or without needles, Catheter, I.V. Cannula, etc.)**

SL	Name of devices used	Strength & Dosages and pack size of the formulation	No of units utilized/billed	Name of the manufacturer/market ing company	Price to Distributer as per data submitted by Company (PTD) (Rs.)	The purchase price of the hospital (Rs.)	Printed MRP on the drugs/ devices/unit (Rs.)	Total Billed to the Patient including taxes (Rs.)	Margin on Procurement price (%)	Margin on Price to Distributor (%)
39	Syringe L.Lock5ml w.needle	5ml with Needle	14	Hindustan Manufacturing Devices	2.39	2.10	10.00	140.00	376%	318%
40	Syring L.Slip 20ml w/o needle	20ml Without needle	54	Hindustan Manufacturing Devices	6.73	6.57	31.00	1,674.00	372%	361%